Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX

Viking Therapeutics

Viking Therapeutics patent portfolio — 15 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
San Diego, USA HQ
2012 Founded
60 Employees
Public company Type
VKTX · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2012
Employees
60
Programs
6
Drugs
3
Patents
15
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Viking Therapeutics patents

15 pharmaceutical patents indexed for Viking Therapeutics. 0 expire within 24 months.

Viking Therapeutics has 15 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

15 patents

Patent portfolio

  1. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12318426

    Compositions and methods for the treatment of metabolic and liver disorders

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12102646

    Compositions for the treatment of fibrosis and inflammation

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12083184

    Hydrogel prodrug for treatment

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11951114

    Use of thyroid beta-agonists

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11752217

    Hydrogel prodrug for treatment

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11744873

    Compositions and methods for the treatment of metabolic and liver disorders

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11707472

    Compositions for the treatment of fibrosis

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11701431

    Hydrogel prodrug for treatment

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11351183

    Use of thyroid beta-agonists

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11331395

    Hydrogel prodrug for treatment

    Expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11273226

    Hydrogel prodrug for treatment

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11202789

    Method of treating glycogen storage disease

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10413616

    Hydrogel prodrug for treatment

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10406241

    Hydrogel prodrug for treatment

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Viking Therapeutics have?

15 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Viking Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.